Latest Loss Reporting News

Growthpoint Properties Australia reported a statutory net profit of $90.1 million for FY26, underpinned by record leasing activity and achievement of its Net Zero Target. The group maintained strong portfolio occupancy at 96%, grew funds under management, and provided FY27 guidance reflecting ongoing macroeconomic caution.

BauMart Holdings has secured $244,463 through a placement of over 24 million shares at one cent each, aiming to bolster its BuildMart Modular operations and general working capital.

Atomos Limited has turned a corner in FY26, posting over 20% sales growth to around $40 million and swinging to EBITDA profitability after prior losses, boosted by new product launches and the strategic acquisition of Flanders Scientific.

The Star Entertainment Group reported a significant improvement in quarterly EBITDA loss alongside stable revenue, completing key joint venture exit and refinancing milestones that boosted liquidity to $267 million.

Lendlease is selling its 25.1% stake in the Keyton Retirement Living Trust to Aware Super for $525 million, part of a broader $3.4 billion capital recycling push aimed at debt reduction.

SciDev Ltd has announced an immediate CEO transition with CFO Todd Scott stepping up to lead, as outgoing CEO Seán Halpin moves to an advisory role. The company also names John Gardiner as interim CFO while seeking a permanent replacement.

Hydrix Limited has launched the retail phase of its accelerated entitlement offer aiming to raise up to $8.18 million by issuing six new shares per existing share at $0.005 each, plus free options. The institutional component has closed, and retail shareholders have until 5 June to participate.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Carnegie Clean Energy has dismissed any undisclosed information behind a recent surge in its ASX share price, attributing the spike to increased trading activity on its US OTC market.

Yowie Group’s June quarter reveals a revenue decline to $1.93 million, offset by improved operating cash inflows and a successful $516,000 capital raise. The company advances product launches in North America and Australia while undergoing significant board restructuring.

Percheron Therapeutics has closed a $2.2 million entitlement offer to advance its HMBD-002 immuno-oncology candidate towards a phase II trial in 2026, backed by strong shareholder and new investor support.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.